Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev

Akebia Therapeutics, Inc.

2025-Q1 EPS reported $0.03 revenue$57,336,000

Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.
Net income of $6.1M in Q1 2025 versus net loss of $18.0M in Q1 2024; driven by Vafseo and Auryxia sales.
Auryxia net revenues $43.8M (up from $31.0M YoY); market exclusivity lost March 20, 2025 but no ANDA approved.
Cash and equivalents $113.4M as of March 31, 2025, up from $51.9M at Dec 31, 2024, after $50M public offering.
Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD patients in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.